ADA (HumiraTM, AbbVie Inc.)is a recombinant, fully human IgG1 monoclonal antibody licensed subcutaneously for RA, CD, UC and psoriasis, whereas CER (CimziaTM, UCB, Inc), a pegylated, humanised Fab fragment of an anti-TNF-α monoclonal antibody given subcutaneously, is licensed for RA, SA, and PsA and for CD only in the United States. The gene discussed is TNF; the disease is psoriasis.